Tri- and tetrasubstituted pyrazole derivates: Regioisomerism switches activity from p38MAP kinase to important cancer kinases

Journal of Medicinal Chemistry

Volumn 55, Issue 2, 2012, Pages 961-965

  Thaher, Bassam Abu ^a   Arnsmann, Martina ^b   Totzke, Frank ^c   Ehlert, Jan E ^c   Kubbutat, Michael H G ^c   Schächtele, Christoph ^c   Zimmermann, Markus O ^b   Koch, Pierre ^b   Boeckler, Frank M ^b   Laufer, Stefan A ^b  

^a ISLAMIC UNIVERSITY OF GAZA   (Palestine)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c PROQINASE GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 FLUOROPHENYL) 4 ([PYRIDIN 4 YL) 1 (ARYL)] 1H PYRAZOL 5 AMINE; 4 (4 FLUOROPHENYL) 3 [(PYRIDIN 4 YL) 1 (2,4,6 TRICHLOROPHENYL)] 1H PYRAZOL 5 AMINE; 4 (4 FLUOROPHENYL) 3 [(PYRIDIN 4 YL) 1 (ARYL)] 1H PYRAZOL 5 AMINE; ANTINEOPLASTIC AGENT; B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN KINASE P60; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; HYDROLYSIS; IC 50; ISOMERISM; MOLECULARLY TARGETED THERAPY;

ANTINEOPLASTIC AGENTS; ENZYME ASSAYS; MODELS, MOLECULAR; MUTATION; NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84856380089     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201391u     Document Type: Article

References (20)

1. Sachse, A.; Penkova, L.; Noel, G.; Dechert, S.; Varzatskii, O. A.; Fritsky, I. O.; Meyer, F. Efficient syntheses of some versatile 3,5-bifunctional pyrazole building blocks Synthesis 2008, 800-806 (Pubitemid 351397565)
2. Dvorak, C. A.; Rudolph, D. A.; Ma, S.; Carruthers, N. I. Palladium-catalyzed coupling of pyrazole triflates with arylboronic acids J. Org. Chem. 2005, 70, 4188-4190 (Pubitemid 40675357)
3. Kumar, G. G.; Vikas, K.; Vinod, K. Pyrazoles as potential anti-obesity agents Res. J. Chem. Environ. 2011, 15, 90-103
4. Deng, X. H.; Mani, N. S. Base-mediated reaction of hydrazones and nitroolefins with a reversed regio selectivity: A novel synthesis of 1,3,4-trisubstituted pyrazoles Org. Lett. 2008, 10, 1307-1310
5. Adams, J. L.; Gallagher, T. F.; Lee, J. Imidazole derivatives and their use as cytokine inhibitors. (SmithKline Beecham Corp., USA. 1993-US674[9314081], 70. WO. 13-1-1993.
6. Abu Thaher, B.; Koch, P.; Schattel, V.; Laufer, S. Role of the hydrogen bonding heteroatom-Lys53 interaction between the p38 alpha mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors J. Med. Chem. 2009, 52, 2613-2617
7. Bracht, C.; Hauser, D. R. J.; Schattel, V.; Albrecht, W.; Laufer, S. A. Synthesis and biological testing of N-aminoimidazole-based p38 alpha MAP kinase inhibitors ChemMedChem 2010, 5, 1134-1142
8. Minami, N.; Sato, M.; Hasumi, K.; Yamamoto, N.; Keino, K.; Matsui, T.; Kanada, A.; Ohta, S.; Saito, T.; Sato, S.; Asagarasu, A.; Doi, S.; Kobayashi, M.; Sato, J.; Asano, H. Preparation of aminopyrazole derivatives as p38 mitogen-activated protein (p38MAP) kinase inhibitors. [WO2000039116A1], 111. 6-7-2000. Teikoku Hormone Mfg. Co., Ltd.: Japan.
9. Liu, Y. X.; Liu, S. H.; Li, Y. H.; Song, H. B.; Wang, Q. M. Synthesis and biological evaluation of arylhydrazinocyanoacrylates and N-aryl pyrazolecarboxylates Bioorg. Med. Chem. Lett. 2009, 19, 2953-2956
10. Makino, K.; Kim, H. S.; Kurasawa, Y. Synthesis of pyrazoles J. Heterocycl. Chem. 1998, 35, 489-497 (Pubitemid 128498315)
11. Deng, X. H.; Mani, N. S. Regioselective synthesis of 1,3,5-tri- and 1,3,4,5-tetrasubstituted pyrazoles from N-arylhydrazones and nitroolefins J. Org. Chem. 2008, 73, 2412-2415 (Pubitemid 351497775)
12. Patel, M. V.; Bell, R.; Majest, S.; Henry, R.; Kolasa, T. Synthesis of 4,5-diaryl-1H-pyrazole-3-ol derivatives as potential COX-2 inhibitors J. Org. Chem. 2004, 69, 7058-7065 (Pubitemid 39363001)
13. Peruncheralathan, S.; Ehan, T. A.; Ila, H.; Junjappa, H. Regioselective synthesis of 1-aryl-3,4-substituted/annulated-5-(methylthio)pyrazoles and 1-aryl-3-(methylthio)-4,5-substituted/annulated pyrazoles J. Org. Chem. 2005, 70, 10030-10035 (Pubitemid 41689169)
14. Silvestri, R.; Cascio, M. G.; La Regina, G.; Piscitelli, F.; Lavecchia, A.; Brizzi, A.; Pasquini, S.; Botta, M.; Novellino, E.; Di Marzo, V.; Corelli, F. Synthesis, cannabinoid receptor affinity, and molecular modeling studies of substituted 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides J. Med. Chem. 2008, 51, 1560-1576 (Pubitemid 351438840)
15. Goettert, M.; Graeser, R.; Laufer, S. A. Optimization of a nonradioactive immunosorbent assay for p38 alpha mitogen-activated protein kinase activity Anal. Biochem. 2010, 406, 233-234
16. Herbst, R. S.; Johnson, D. H.; Mininberg, E.; Carbone, D. P.; Henderson, T.; Kim, E. S.; Blumenschein, G.; Lee, J. J.; Liu, D. D.; Truong, M. T.; Hong, W. K.; Tran, H.; Tsao, A.; Xie, D.; Ramies, D. A.; Mass, R.; Seshagiri, S.; Eberhard, D. A.; Kelley, S. K.; Sandler, A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J. Clin. Oncol. 2005, 23, 2544-2555
17. Smalley, K. S. M.; Herlyn, M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics Tumor Prog. Ther. Resist. 2005, 1059, 16-25 (Pubitemid 43211606)
18. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD Protein: Struct., Funct., Genet. 2003, 52, 609-623 (Pubitemid 37034158)
19. Petrelli, A.; Giordano, S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage Curr. Med. Chem. 2008, 15, 422-432 (Pubitemid 351472408)
20. Traxler, P.; Furet, P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors Pharm. Ther. 1999, 82, 195-206 (Pubitemid 29255915)